How is phenylalanine converted to tyrosine, and how does pegvaliase (phenylalanine ammonia lyase) provide an alternative conversion pathway?

Phenylalanine Conversion Pathways

Phenylalanine is normally converted to tyrosine by the enzyme phenylalanine hydroxylase (PAH) with its cofactor tetrahydrobiopterin (BH4) in the liver, while pegvaliase provides an alternative pathway by converting phenylalanine directly to trans-cinnamic acid and ammonia, bypassing the need for functional PAH enzyme. 1

Normal Physiological Pathway

In healthy individuals, the hepatic enzyme PAH works together with BH4 to hydroxylate phenylalanine (Phe) to tyrosine (Tyr). This conversion:

• Maintains normal blood Phe levels
• Produces tyrosine for synthesis of critical metabolites including melanin, dopamine, and norepinephrine
• Accounts for approximately 16% of phenylalanine flux under normal basal conditions 2
• Occurs at a rate of approximately 5.83 μmol/kg/hour in healthy postabsorptive adults 2

The conversion rate demonstrates substrate activation—meaning PAH activity increases exponentially with rising phenylalanine concentrations, rather than linearly 2. This physiological regulation is critical because it allows the body to respond to varying dietary protein intake.

PAH Deficiency and Its Consequences

When PAH is deficient (as in phenylketonuria), this primary conversion pathway fails, resulting in:

• Elevated blood Phe levels (>600 μmol/L in untreated PKU)
• Low tyrosine levels (making tyrosine conditionally essential)
• Deficiency of tyrosine-derived neurotransmitters
• Profound intellectual disability if untreated 1

Pegvaliase: The Alternative Pathway

Pegvaliase is a PEGylated recombinant phenylalanine ammonia lyase (PAL) enzyme derived from Anabaena variabilis. It provides enzyme substitution therapy through a completely different biochemical mechanism 3:

Key mechanistic differences:

• Does NOT produce tyrosine—instead converts Phe to trans-cinnamic acid and ammonia
• Works independently of BH4 cofactor
• Functions as an exogenous enzyme (injected subcutaneously)
• Requires immune tolerization over time as clearance declines with continued exposure 4

Clinical Efficacy of the Alternative Pathway

Long-term data from the PRISM trials demonstrate pegvaliase's effectiveness 3:

• Mean blood Phe decreased from 1232.7 μmol/L at baseline to 311.4 μmol/L at 24 months (68.7% reduction)
• 60.7% of patients achieved Phe ≤360 μmol/L (the ACMG-recommended upper limit) within 24 months
• 51.2% achieved Phe ≤120 μmol/L (normal population range)

Real-world outcomes confirm these findings, with 55% achieving goal at 12 months and 77% at 24 months 5.

Critical Clinical Considerations

Tyrosine supplementation remains necessary: Because pegvaliase does not produce tyrosine (unlike the natural PAH pathway), patients still require tyrosine through diet or medical foods to prevent deficiency of this now-essential amino acid 1.

Immune tolerization creates a therapeutic window: The pharmacokinetic model shows a critical period at blood Phe levels of 120-200 μmol/L where volatility increases—this represents impending but incomplete tolerization. Reducing pegvaliase dose or liberalizing diet prematurely during this phase can cause marked Phe increases 4. Continued exposure is essential to achieve full tolerization.

Safety profile: Anaphylaxis occurs in approximately 31% of patients, predominantly during maintenance phase 5. However, 99% of adverse events are mild-to-moderate, with injection site reactions (90%) and arthralgia (69%) being most common 3, 5.

Pregnancy considerations: ACMG makes no recommendation for pegvaliase use during pregnancy due to insufficient evidence, despite one case report of healthy infant outcome 6. The natural PAH pathway (when functional) or dietary management with sapropterin remain preferred approaches during pregnancy.

Therapeutic Staging Approach

Based on tolerization kinetics, pegvaliase therapy follows three stages 4:

1. Tolerance induction phase: Gradual dose escalation while maintaining dietary Phe restriction
2. Diet liberalization phase: Once stable Phe reduction achieved, carefully increase dietary Phe intake
3. Dose adjustment phase: After full tolerization (dietary Phe and blood Phe become uncoupled), optimize maintenance dosing

Combination therapy with sapropterin and pegvaliase may accelerate time to Phe goal attainment compared to pegvaliase monotherapy 5, suggesting the two pathways can work synergistically when residual PAH activity exists.